Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit

Core Insights - Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, showcasing its commitment to advancing precision nerve-targeted treatments [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Technology Development - Initial development of the technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]